[
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE): Among Blue Chip Stocks to Invest in at 52-Week Lows",
    "summary": "We recently published a list of 11 Blue Chip Stocks to Invest in at 52-Week Lows. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other blue chip stocks to invest in at 52-week lows. For the first time since 2023, the S&P 500 was seen in […]",
    "url": "https://finnhub.io/api/news?id=9c97609c35d7906278c4bc80eaab32df8604c761804f75aa646f796b9be8a29f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743338870,
      "headline": "Pfizer Inc. (PFE): Among Blue Chip Stocks to Invest in at 52-Week Lows",
      "id": 133619049,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We recently published a list of 11 Blue Chip Stocks to Invest in at 52-Week Lows. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other blue chip stocks to invest in at 52-week lows. For the first time since 2023, the S&P 500 was seen in […]",
      "url": "https://finnhub.io/api/news?id=9c97609c35d7906278c4bc80eaab32df8604c761804f75aa646f796b9be8a29f"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors",
    "summary": "Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain for investors.",
    "url": "https://finnhub.io/api/news?id=e065d0a1e1188ee694cc2bc6539fc5b42f511784f8985ea5256abcfe2f272f87",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743310800,
      "headline": "Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors",
      "id": 133598030,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1453972690/image_1453972690.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain for investors.",
      "url": "https://finnhub.io/api/news?id=e065d0a1e1188ee694cc2bc6539fc5b42f511784f8985ea5256abcfe2f272f87"
    }
  },
  {
    "ts": null,
    "headline": "abrdn Healthcare Investors Q4 2024 Commentary",
    "summary": "The equity portion of the Abrdn Healthcare Investors Fund fell (gross of fees) but outperformed its custom benchmark over the quarter. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=82f91dbf63848ebe808f64808c8e5edf8521e08d31f59b25f79fc61ada48f984",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743303000,
      "headline": "abrdn Healthcare Investors Q4 2024 Commentary",
      "id": 133590926,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/91598774/image_91598774.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "The equity portion of the Abrdn Healthcare Investors Fund fell (gross of fees) but outperformed its custom benchmark over the quarter. Click here to read the full commentary.",
      "url": "https://finnhub.io/api/news?id=82f91dbf63848ebe808f64808c8e5edf8521e08d31f59b25f79fc61ada48f984"
    }
  }
]